Arvinas presents positive Phase 1 data for ARV-102; biomarker modulation in CSF seen

ARVINAS, INC.

ARV-102 well tolerated up to 200 mg single dose and 80 mg daily; no SAEs or discontinuations.
Dose-dependent CSF exposure confirmed in healthy volunteers and Parkinson's patients.
Daily doses ≥20 mg reduced PBMC LRRK2 by >90%; 200 mg dose in patients achieved 97% reduction.
CSF proteomics showed decreases in lysosomal and neuroinflammatory microglial markers after 14 days.
Arvinas plans to report multiple-dose Parkinson's data in 2026 and initiate Phase 1b PSP trial H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.